InnovAge to Announce Fiscal Fourth Quarter 2023 Financial Results and Host Conference Call Tuesday, September 12, 2023

1 year ago

DENVER, Aug. 29, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in…

Better Life Partners Raises $26.5 Million in Series B Financing to Amplify and Scale its Hybrid Whole-Health Solutions for Substance Use Disorders

1 year ago

Funding will expand company’s technology-enabled, alternate-payment care model, bringing its innovative and effective approach to more people in needBOSTON, Aug.…

Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference

1 year ago

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of…

Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

1 year ago

Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion rates of 3,000mg via IV…

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%  

1 year ago

The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVEZORYVE is a once-daily, steroid-free…

Longeveron to Participate in the 149th Annual National Investment Banking Association Conference

1 year ago

MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology…

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

1 year ago

Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid…

MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference

1 year ago

CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™…

Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update

1 year ago

VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated…